投稿信息
投稿信息
审稿周期
投稿命中率
审稿费用
暂无数据
版面费用
暂无数据
中国人发表比例
2018年中国人文章占该期刊总数量暂无数据 (2017年为暂无数据)
自引率
暂无数据
年文章数
0
投稿链接
未知
作者需知
暂无数据
NCBI查询
偏重的研究方向
暂无数据
期刊简介
稿件收录要求
稿件收录要求
Published by Thomson Current Drugs.
ISSN: 1472-4472.
Current Opinion in Investigational Drugs is a monthly publication covering all therapeutic areas, in recognition of the increasingly multi-disciplinary nature of modern drug discovery and development. With Current Opinion in Investigational Drugs, we aim to help the reader by providing in a systematic manne critical reviews of selected areas of investigational drug research, expert evaluation of selected drugs currently in clinical trials, selection of the most interesting papers and patents, annotated by experts. Six therapeutic categories are covered with each being featured in separate journal issues, and each therapeutic area being covered twice-yearly. The broad therapeutic categories and the specialist topics within each are as follows: Anti-infectives Antifungals and antiparasitics; antibacterials (b-lactams, glycopeptides and other agents); antibacterials (quinolones, macrolides and oxazolidinones); vaccines; antivirals (HIV); antivirals (non-HIV); Anti-inflammatory, Immunologicals and Biologicals Musculoskeletal; respiratory; dermatology; nervous system; transplantation; Cardiovascular and Renal Hypertension and renal failure; stroke and angina; arrhythmia and heart failure; antithrombotics; hemostasis and hematological diseases; atherosclerosis, hypercholesterolemia and heart disease; Endocrine and and Metabolics Diabetes, reproductive endocrinology, hormone disorders, bone metabolism and obesity; Central and Peripheral Nervous System Pain; neuro-urology and neurogastroenterology; neurodegenerative and cognitive disorders; affective/behavioral/personality disorders and substance abuse; neurology and neuroprotection; schizophrenia and psychosis; Oncological Cell signaling modulators; cytotoxic drugs; immunotherapeutic drugs and monoclonal antibodies; protein therapeutics, including growth factors; gene therapy; antisense inhibitors
Current Opinion in Investigational Drugs is a monthly publication covering all therapeutic areas, in recognition of the increasingly multi-disciplinary nature of modern drug discovery and development. With Current Opinion in Investigational Drugs, we aim to help the reader by providing in a systematic manne critical reviews of selected areas of investigational drug research, expert evaluation of selected drugs currently in clinical trials, selection of the most interesting papers and patents, annotated by experts. Six therapeutic categories are covered with each being featured in separate journal issues, and each therapeutic area being covered twice-yearly. The broad therapeutic categories and the specialist topics within each are as follows: Anti-infectives Antifungals and antiparasitics; antibacterials (b-lactams, glycopeptides and other agents); antibacterials (quinolones, macrolides and oxazolidinones); vaccines; antivirals (HIV); antivirals (non-HIV); Anti-inflammatory, Immunologicals and Biologicals Musculoskeletal; respiratory; dermatology; nervous system; transplantation; Cardiovascular and Renal Hypertension and renal failure; stroke and angina; arrhythmia and heart failure; antithrombotics; hemostasis and hematological diseases; atherosclerosis, hypercholesterolemia and heart disease; Endocrine and and Metabolics Diabetes, reproductive endocrinology, hormone disorders, bone metabolism and obesity; Central and Peripheral Nervous System Pain; neuro-urology and neurogastroenterology; neurodegenerative and cognitive disorders; affective/behavioral/personality disorders and substance abuse; neurology and neuroprotection; schizophrenia and psychosis; Oncological Cell signaling modulators; cytotoxic drugs; immunotherapeutic drugs and monoclonal antibodies; protein therapeutics, including growth factors; gene therapy; antisense inhibitors
